e.l.f. Beauty stock plummets 20% as revenue and guidance fall short of expectations
Investing.com -- Tectonic Therapeutic (NASDAQ:TECX) stock surged 18% after the company announced positive topline results from its Phase 1b Part B clinical trial for TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (PH-HFrEF).
The biopharmaceutical company reported that a single intravenous dose of TX45, a long-acting Fc-relaxin fusion protein, showed meaningful improvements in both left heart function and pulmonary hemodynamics in PH-HFrEF patients. The drug was well tolerated with no serious or severe adverse events.
Key hemodynamic results included a 29.2% mean reduction in pulmonary capillary wedge pressure and a 17.3% mean increase in cardiac output. For patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) with pulmonary vascular resistance greater than 3 Wood units, TX45 demonstrated a 19.7% mean reduction in pulmonary vascular resistance.
The data also showed persistent effects at day 29 post-dose, with echocardiography revealing a 19.4% improvement in left ventricular ejection fraction and a 20.3% improvement in right ventricular fractional area of change.
"These results in PH-HFrEF open up the potential to expand into this additional patient population with significant unmet need and no approved therapies, pending results from the ongoing APEX Phase 2 clinical trial," said Alise Reicin, M.D., President and CEO of Tectonic.
The positive findings from this trial build on previous results from the Phase 1b Part A trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF). Tectonic is currently conducting the APEX Phase 2 clinical trial to evaluate TX45 over a 24-week treatment period in PH-HFpEF patients, with topline results expected in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.